Safety and efficacy of dostarlimab monotherapy as first-line treatment in programmed cell death-ligand 1–positive recurrent/metastatic head and neck squamous cell carcinoma: Results from a phase 2 trial.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Harvard University, Dana-Farber Cancer Institute, National Cancer Center Hospital East, Humanitas University, IRCCS Humanitas Research Hospital, GlaxoSmithKline (Switzerland), GlaxoSmithKline (Canada), GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States), University Health Network, University of Toronto, Princess Margaret Cancer Centre
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162486711
Cites:
Cited by:
Related to: